Dallas, TX: ReportsandReports announce it will carry Daiichi Sankyo Co., Ltd: PharmaVitae Profile Market Research Report in its Store.

Browse complete Daiichi Sankyo Co., Ltd: PharmaVitae Profile Report

Introduction

This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

• Benchmark Daiichi Sankyo’s performance against key rivals in the prescription pharmaceutical sector
• Assess the importance of Daiichi Sankyo’s olmesartan antihypertensives franchise (Benicar, Benicar HCT and Azor) is to the company’s outlook
• Evaluate the prospects of the company’s key launch product, Effient (prasugrel) which is being co-developed with Eli Lilly

Table Of Contents

CHAPTER 1 ABOUT THIS PROFILE 2

Executive summary 2

Quarterly news update 2

Company introduction 2

Company sales 2

Company financials 2

Key products and competitors 3

Data sourcing 3

Sales data 3

Analyst consensus 3

CHAPTER 2 EXECUTIVE SUMMARY 4

Key findings 4

Prescription pharmaceutical sales performance, 2001-13 5

Financial performance, 2001-13 6

Daiichi Sankyo: PharmaVitae forecasts at a glance 7

Strategic insight 8

Introduction 8

Product strategic insight 8

Olmesartan franchise central to Daiichi Sankyo’s future growth 8

Uncertainty regarding generic entry 9

Two scenarios for olmesartan 10

Some genericization already priced into the upside scenario 13

Effient: Daiichi Sankyo’s much-needed new revenue stream 13

M&A strategic insight 15

M&A strategic insight 15

Ranbaxy acquisition 15

SWOT analysis 17

SWOT analysis 17

Strengths 17

Weaknesses 19

Opportunities 19

Threats 20

CHAPTER 3 QUARTERLY NEWS UPDATE 23

Product developments 23

Deals and alliances 24

Product deals 24

Technology deals 26

M&A activity 27

Company announcements 30

Future product milestones 34

CHAPTER 4 COMPANY INTRODUCTION 35

Key findings 35

Background 36

M&A history 36

Ranbaxy acquisition 37

Zenotech: opportunity in biopharmaceuticals 37

Current corporate structure 38

CHAPTER 5 COMPANY SALES 39

Key findings 39

Prescription pharmaceutical sales and growth rate analysis, 2001-13 40

Product analysis 42

Product analysis, 2001-07 43

Product analysis, 2007-13 46

Therapy area analysis 50

Therapy area analysis, 2001-07 51

Therapy area analysis, 2007-13 54

Therapy area focus, 2001-13 57

Geographic analysis 59

Geographic analysis, 2001-07 61

Geographic analysis, 2007-13 65

Geographic focus, 2001-13 69

Launch/core/expiry analysis 71

Explanation of launch/core/expiry analysis 71

Launch analysis, 2007-13 72

Core analysis, 2007-13 73

Expiry analysis, 2007-13 74

Launch/core/expiry configuration, 2007-13 76

Molecule type analysis 77

Molecule type analysis, 2001-07 78

Molecule type analysis, 2001-07 78

Molecule type analysis, 2007-13 80

Externalization analysis 83

Externalization analysis, 2001-07 84

Externalization analysis, 2007-13 87

CHAPTER 6 COMPANY FINANCIALS 91

Key findings 91

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 92

Financial statements, 2001-07 94

Profit and loss account, 2001-07 94

Balance sheet, 2001-07 96

Operating costs and profit analysis 98

Operating costs and profit analysis, 2001-07 99

Operating cost ratio and profit margin analysis, 2001-07 100

Operating cost ratio and profit margin analysis, 2007-13 101

Operating costs and profit analysis, 2007-13 103

Return on capital employed analysis 105

Capital employed analysis, 2001-07 106

Return on capital employed (RoCE) analysis, 2001-07 108

CHAPTER 7 KEY PRODUCTS AND COMPETITORS 111

Key findings 111

Overview 112

Cardiovascular 113

Benicar 113

Overview 113

Sales forecast 114

Benicar HCT 116

Overview 116

Sales forecast 117

Azor 119

Overview 119

Sales forecast 120

WelChol 122

Overview 122

Sales forecast 123

Mevalotin 125

Overview 125

Sales forecast 126

Hematology 128

Effient 128

Overview 128

Sales forecast 129

Infectious diseases 131

Cravit 131

Overview 131

Sales forecast 132

Endocrine, metabolic & genetic disorders 134

Rivoglitazone 134

Overview 134

Sales forecast 135

Browse complete Daiichi Sankyo Co., Ltd: PharmaVitae Profile Report

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports RSS

Browse all Latest Report

Related Reports:

Daiichi Sankyo Co., Ltd.

Daiichi Sankyo Co., Ltd. – SWOT Analysis

Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/